Vaxart, Inc.

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Vaxart reports solid Q1 earnings, progresses in vaccine development

Vaxart's Q1 2024 performance reflects financial stability and progress in vaccine development, particularly with positive Phase I trial results for their norovirus vaccine.
While the company faces challenges in funding, manufacturing, and program prioritization, opportunities lie in advancing COVID-19 vaccine trials and regulatory engagements.
By addressing concerns and leveraging opportunities effectively, Vaxart can strengthen its position in the vaccine market and drive future growth and innovation.

Vaxart reports strong Q3 revenue, advances in COVID and norovirus

Vaxart's Q3 2024 earnings call highlighted revenue from government contracts, progress in COVID, norovirus, and HPV programs, and promising trial data.
The company faces challenges in study enrollment, resource allocation, and regulatory compliance but remains open to collaborations and global vaccine development.
With a cash runway into 2026, Vaxart is well-positioned to leverage market demand for their oral pill vaccine candidates and drive future growth.
Strong performance, constructive FDA feedback, and market opportunities position Vaxart for continued success in vaccine development and partnerships.

Vaxart reports Q4 revenue, faces COVID-19 study halt challenges

Vaxart's Q4 2024 earnings call highlighted revenue of $28.7 million, progress in norovirus program, and a temporary halt in the COVID-19 study. The company's strengths lie in innovative vaccine development, research capabilities, and commitment to safety and efficacy. Challenges include the stop work order impact, funding needs, and navigating market dynamics, while opportunities exist in new vaccine constructs and partnerships. Strategic planning and addressing challenges will be crucial for Vaxart's future growth and success in vaccine development.

Vaxart progresses in vaccine trials, addresses shareholder queries and transitions CFO

Vaxart advances COVID-19 and Norovirus vaccine trials, CFO transition noted. Facing communication hurdles but aims for transparency. Addressing shareholder queries and considering strategic moves for growth.

Vaxart reports solid Q2 earnings amidst program advancements and challenges

Vaxart's Q2 2025 earnings call highlighted revenue growth, program advancements, and financial prudence. Despite challenges in COVID-19 trial progress and NASDAQ compliance, the company remains resilient. Opportunities for partnerships, regulatory compliance, and program advancements signal a promising future for Vaxart.

Vaxart secures $700M partnership, reports strong Q3 revenue growth

Vaxart's Q3 performance reflects revenue growth and a strengthened financial position, supported by a significant partnership and promising vaccine developments. While facing funding challenges for upcoming trials, Vaxart's successful Phase I results and strategic partnership offer opportunities for growth and innovation.

Vaxart reports strong Q4 revenue growth and advances in vaccine development

Vaxart's Q4 2025 performance reflects financial strength and promising developments in their vaccine programs, particularly in COVID-19 and norovirus vaccines. While facing challenges in meeting data release expectations and sustaining R&D momentum, the company's focus on oral vaccines and ongoing studies present growth opportunities. Optimism expressed by executives underscores Vaxart's confidence in their vaccine portfolio and future prospects for market success and expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.